---
schema_version: "secwatch.filing_event.v1"
accession: "0001171843-26-001506"
form_type: "8-K"
ticker: "FLNA"
cik: "0001069530"
company_name: "FILANA THERAPEUTICS, INC."
filed_at: "2026-03-12T23:59:59+00:00"
generated_at: "2026-05-15T12:52:58.904748+00:00"
event_type: "earnings"
sentiment: "negative"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Filana Therapeutics reports 2025 net loss of $91M; cash burn guidance and TSC program clinical hold detailed

## Summary
- Net loss $91.0M ($1.88/share) vs $24.3M ($0.53) in 2024; cash $95.5M at Dec 31, 2025.
- Est. cash at June 30, 2026 at $47-50M; net cash use H1 2026 $14-17M plus $31.25M litigation settlement payment.
- R&D expenses fell 62% to $26.6M after Alzheimer's program phase-out; TSC program on clinical hold since Dec 2025.
- G&A expenses $68.8M include $31.3M securities litigation contingency; no insurance recoveries.
- Name change to Filana Therapeutics reflects focus on filamin A modulation for TSC-related epilepsy.

## SEC filing metadata
- accession: 0001171843-26-001506
- form_type: 8-K
- ticker: FLNA
- cik: 0001069530
- company_name: FILANA THERAPEUTICS, INC.
- filed_at: 2026-03-12T23:59:59+00:00
- event_type: earnings
- sentiment: negative
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1069530/000117184326001506/0001171843-26-001506-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1069530/000117184326001506/f8k_031226.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001171843-26-001506
- JSON: https://secwatch.observer/filing/0001171843-26-001506.json
- Plain text: https://secwatch.observer/filing/0001171843-26-001506.txt

## Key facts
- Earnings Releases
  FILANA THERAPEUTICS, INC. reported the fourth quarter and year ended December 31, 2025 results: net income Net loss for 2025 was $91.0 million, EPS $1.88 per share.
  - Period: the fourth quarter and year ended December 31, 2025
  - Net income: Net loss for 2025 was $91.0 million
  - EPS: $1.88 per share
  - Result: reported results
  source text: Filana Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results
  evidence_url: https://www.sec.gov/Archives/edgar/data/1069530/000117184326001506/0001171843-26-001506-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.